Jordan Gauthier

Assistant Professor

Fred Hutchinson Cancer Research Center

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Jordan Gauthier is an Assistant Professor at the Fred Hutchinson Cancer Research Center in the United States. His research focuses on CAR T-cell therapy, particularly in the context of various B-cell malignancies and its implications on patient outcomes. Recent publications include analyses of CD19 CAR T-cell therapy in lymphoma and the impacts of cytomegalovirus reactivation in patients undergoing such treatments.

Articles (10)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Year:

2021

Year:

2020

Year:

2020

Collaborators (5)

Julio Delgado

Head

Hospital Clínic de Barcelona

SPAIN

View details

Mazyar Shadman

Fred Hutchinson Cancer Research Center

UNITED STATES

View details

Hans-Peter Kiem

Fred Hutchinson Cancer Research Center

UNITED STATES

View details

Takahiro Miyazaki

VP, Head of Research

Moderna Therapeutics (United States)

UNITED STATES

View details

Damian Green

Fred Hutchinson Cancer Research Center

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Jordan Gauthier

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

CD19 CAR T‐Cell Therapy for Primary Mediastinal Large B‐Cell Lymphoma: A CIBMTR Analysis

The impact of CMV reactivation on mortality after chimeric antigen receptor T-cell therapy

Phase 1 study of CD19 CAR T-cell therapy harboring a fully human scFv in CAR-naïve adult patients with B-ALL

Answering the “Doctor, can CAR-T therapy cause cancer?” question in clinic

A novel polymer-conjugated human IL-15 improves efficacy of CD19-targeted CAR T-cell immunotherapy

Clash of the titans: axi-cel versus tisa-cel for advanced-stage DLBCL

Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL

Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies

CAR T-cell therapy for the management of refractory/relapsed high-grade B-cell lymphoma: a practical overview

Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure

Collaborators (5)

Julio Delgado

Mazyar Shadman

Hans-Peter Kiem

Takahiro Miyazaki

Damian Green

Make your next move.